Shingles Market Expected to Strengthen as Awareness Increases and More Effective Interventions Are Developed by 2032 - DelveInsight

DelveInsight's "Shingles Drugs Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Shingles, historical and forecasted epidemiology as well as the Shingles market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Get a Free sample for the Shingles Drugs Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/sample-request/shingles-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Some of the key facts of the Shingles Drugs Market Report:
• The Shingles therapeutics market in the 7MM is expected to witness a major change in the study period 2019-2032, driven by rising awareness of the disease and incremental healthcare spending across the world, which would expand the size of the market to enable drug manufacturers to penetrate more into the shingles therapeutics market.
• In January 2025, GSK plc announced that the US Food and Drug Administration (FDA) has accepted for review its regulatory application for a prefilled syringe presentation of Shingrix (GSK's Recombinant Zoster Vaccine or RZV) for the prevention of shingles (herpes zoster).
• The Shingles market has witnessed significant growth and evolution as the healthcare industry continues to address the challenges associated with herpes zoster, commonly known as shingles. The market for shingles treatment is driven by the increasing incidence of the disease, primarily among the aging population and individuals with compromised immune systems.
• The Shingles treatment market is driven by the increasing incidence of the disease, primarily among the aging population and individuals with compromised immune systems, creating a growing demand for effective antiviral therapies and preventive vaccines.
• Antiviral medications, such as acyclovir, valacyclovir, and famciclovir, are commonly prescribed to reduce the severity and duration of the rash. These conventional therapies form the backbone of current Shingles treatment algorithms in the United States, Europe, and Japan.
• The Shingles market report provides current treatment practices, emerging drugs, Shingles market share of the individual therapies, and current and forecasted Shingles market size from 2019 to 2032 segmented by seven major markets.
• The report also covers current Shingles treatment market practices/algorithms, Shingles market drivers and market barriers, and Shingles unmet needs to curate the best of the opportunities and assess the underlying potential of the Shingles market.
• Key Shingles Companies: Curevo Inc., Green Cross Corporation, Immorna Therapeutics Inc., ICON plc, Pascoe Pharma, Merck Sharp & Dohme LLC, Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, Jiangsu Rec-Biotechnology Co., Ltd., Changchun BCHT Biotechnology Co., Kaiser Permanente, Astellas Pharma Inc., Epiphany Biosciences, Yung Shin Pharm. Ind. Co., Ltd., and others
• Key Shingles Therapies: Shingrix (Recombinant Zoster Vaccine), acyclovir, valacyclovir, famciclovir, and others
• The Shingles market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Shingles pipeline products will significantly revolutionize the Shingles market dynamics.

Shingles Overview
Shingles, also known as herpes zoster, is a viral infection caused by the reactivation of the varicella-zoster virus, which also causes chickenpox. After a person recovers from chickenpox, the virus remains dormant in the nerve tissue near the spinal cord and brain. Years later, the virus may reactivate, traveling along nerve fibers to the skin, causing a painful rash. Shingles typically presents as a painful, blistering rash that often appears on one side of the body or face. The condition is most common in older adults and individuals with compromised immune systems. Complications can include postherpetic neuralgia (PHN), a persistent pain that can last for months or even years after the rash has healed.

To Know in detail about the Shingles market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Shingles Market Forecast https://www.delveinsight.com/sample-request/shingles-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Shingles Epidemiology
The Shingles epidemiology section provides insights about the historical and current Shingles patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Shingles market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Shingles Epidemiology Segmentation:

The Shingles market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalent Cases of Shingles in the 7MM
• Diagnosed Prevalent Cases of Shingles in the 7MM
• Age-specific Prevalence of Shingles in the 7MM
• Gender-specific Prevalence of Shingles in the 7MM
• Complications-specific Prevalent Cases of Shingles in the 7MM
• Treated Cases of Shingles in the 7MM

Download the report to understand which factors are driving Shingles epidemiology trends @ Shingles Epidemiology Forecast https://www.delveinsight.com/sample-request/shingles-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Shingles Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential Shingles drugs recently launched in the Shingles market or expected to be launched in the market during the study period 2019-2032. The analysis covers Shingles market uptake by drugs; patient uptake by therapies; and sales of each drug.
Moreover, the Shingles Drugs Uptake helps in understanding the drugs with the most rapid uptake, and reasons behind the maximal use of new Shingles drugs, and allows the comparison of the drugs based on Shingles market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Shingles Pipeline Development Activities. It provides insights into different therapeutic candidates in Phase II and Phase III stages. It also analyses Shingles companies involved in developing targeted therapeutics. It also covers detailed information on collaborations, acquisitions, and mergers, licensing, patent details, and other information for Shingles emerging therapies.

Shingles Therapies and Key Companies
• Shingrix (Recombinant Zoster Vaccine): GlaxoSmithKline - A non-live, recombinant subunit vaccine approved for the prevention of shingles (herpes zoster) and postherpetic neuralgia in adults aged 50 years and older. GSK announced in January 2025 that the FDA has accepted for review its regulatory application for a prefilled syringe presentation of Shingrix.
• Acyclovir: Commonly prescribed antiviral medication for reducing the severity and duration of the shingles rash.
• Valacyclovir: An antiviral prodrug that is converted to acyclovir in the body, used for the treatment of shingles.
• Famciclovir: An antiviral medication used to treat shingles, reducing the severity and duration of the rash.
• Emerging Shingles Therapies: The Shingles pipeline includes several novel therapeutic candidates in Phase II and Phase III stages of development, focusing on novel approaches to treat and improve the disease condition.

Discover more about therapies set to grab major Shingles market share @ Shingles Treatment Landscape https://www.delveinsight.com/sample-request/shingles-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Shingles Market Drivers
• Increasing incidence of shingles: The growing incidence of the disease, primarily among the aging population and individuals with compromised immune systems, is a major driver of the Shingles market.
• Rising awareness of the disease: Growing awareness of shingles and its complications, including postherpetic neuralgia, is leading to earlier diagnosis and treatment, expanding the addressable patient population.
• Incremental healthcare spending: Increasing healthcare spending across the world is expanding the size of the Shingles market, enabling drug manufacturers to penetrate more into the shingles therapeutics market.
• Development of innovative therapies: The emergence of novel therapeutic approaches, including improved antiviral medications and preventive vaccines, is creating significant market opportunities and addressing previously unmet medical needs.
• Expanding vaccine approval: Regulatory milestones such as the FDA's acceptance for review of a prefilled syringe presentation of Shingrix demonstrate ongoing innovation in shingles prevention and treatment.

Shingles Market Barriers
• Limited awareness in certain regions: Despite growing awareness, shingles remains underdiagnosed and undertreated in some regions, limiting market growth.
• High cost of therapies: The high cost of advanced therapies and vaccines presents a significant economic burden on patients and healthcare systems, potentially limiting patient access to optimal care.
• Complications management challenges: Managing complications such as postherpetic neuralgia remains challenging due to the refractory nature of the condition and the limited efficacy of current medications.
• Competition from existing therapies: The Shingles market faces competition from well-established generic antiviral medications, which may limit the uptake of newer, more expensive therapies.
• Reimbursement barriers: Reimbursement challenges and varying coverage policies across different regions can impact patient access to newer therapies and vaccines.

Scope of the Shingles Drugs Market Report
• Study Period: 2019-2032
• Forecast Period: 2023-2032
• Coverage: 7MM
• Key Shingles Companies: Curevo Inc., Green Cross Corporation, Immorna Therapeutics Inc., ICON plc, Pascoe Pharma, Merck Sharp & Dohme LLC, Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, Jiangsu Rec-Biotechnology Co., Ltd., Changchun BCHT Biotechnology Co., Kaiser Permanente, Astellas Pharma Inc., Epiphany Biosciences, Yung Shin Pharm. Ind. Co., Ltd., and others
• Key Shingles Therapies: Shingrix (Recombinant Zoster Vaccine), acyclovir, valacyclovir, famciclovir, and others
• Shingles Therapeutic Assessment: Shingles current marketed and emerging therapies
• Shingles Market Dynamics: Shingles market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Shingles Unmet Needs, KOL's views, Analyst's views, Shingles Market Access and Reimbursement

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.